Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Drugs In Development, 2024 report and make more profitable business decisions.
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features including thickening of the lips, tongue, and nostrils, and delayed development. Treatment includes bone marrow transplantation, enzyme therapy, and gene therapy.
The Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) drugs in development market research report provide comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AngioChem IncApteeus SAS
Bioasis Technologies Inc
Capsida Biotherapeutics Inc
Denali Therapeutics Inc
Duke University
Esteve Pharmaceuticals SA
GC Biopharma Corp
Generium
Immusoft Corp
JCR Pharmaceuticals Co Ltd
Neurogt Inc
RegenxBio Inc
ReqMed Co Ltd
Sigilon Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions